WASHINGTON, D.C. (January 29, 2003) – Richard F. Pops, CEO of Alkermes, Inc., and vice-chair of healthcare for the Biotechnology Industry Organization’s (BIO) Board of Directors, will testify on behalf of BIO at a Senate Appropriations subcommittee hearing on Medicare reimbursement issues tomorrow, Thursday, Jan. 30.
WHO: Richard F. Pops, CEO of Alkermes, Inc, and vice-chair of healthcare for the BIO Board of Directors
WHAT: Labor, Health and Human Services, and Education and Related Agencies Subcommittee of the U.S. Senate Appropriations Committee Hearing on Medicare Reimbursement for Physicians and Hospitals
WHEN: Thursday, January 30, at 9:30 a.m.
WHERE: 192 Dirksen Building
Pops’ testimony will center on the issues of functional equivalence and new Centers for Medicare and Medicaid Services (CMS) regulations, which went into effect Jan. 1, 2003, and could result in limited access to new, innovative drugs for some Medicare recipients.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.
# # #